Astressin-B Research report – Norma – Parcel C

Sarah Campeau    Astressin-B, Research and latest Discoveries    

Parcel C consists in subjects that have been injected with distinct dosages of the compound. The main variable consists in the duration and consistency of the dosages. This means that the sub-groups within this parcel are helping us determine the efficiency of the compound given different dosages, and how the subjects react to an interruption of the injection cycle, the additional inconsistency of the dosages and duration of the treatment.

This Parcel has been divided in 8 sub-groups, all of which have ongoing experiments that require a constant and prolonged evaluation. Below is the fundamental data being collected on Parcel C;

• Does the compound leave any traces after the treatment has been interrupted?
• Do the side-effects cease after the treatment is interrupted?
• Do the results maintain after the interruption of the treatment? If so, how long are they maintained for.
• How do subjects react to extreme dosages of the compound
• How to the test subjects react to dosage fluctuations

One of the most common questions we keep getting is in regards to the efficiency of Astressin-B used in a treatment to treat hair loss in Androgenic Alopecia patients. While I cannot release a great deal of specifics at this moment, rest assured this is being fully contemplated, particularity in this Parcel.
Since most of the data on this particular parcel is still volatile, as it’s an ongoing experiment, we cannot release a lot of information, but we can safely publish the following preliminary data:

• So far the side effects have disappeared after the treatment has stopped on all sub-control groups.
• An unspecified percentage of subjects who had the treatment interrupted started losing hair again.
• An unspecified percentage of subjects who had the treatment interrupted did not start losing hair again
• High dosages of the compound increase significantly the noted side-effects
• High dosages of the compound did not increase the overall efficiency of the compound

I apologize for not being able to specify the subject conditions, but the purpose of these updates is to give our readers an idea of what we are doing and how the experiment is being conducted, not to provide the definite results.

Astressin-B Research report – Norma – Parcel B

Sarah Campeau    Astressin-B, Research and latest Discoveries    

Parcel B consists in an isolated group of subjects that have been given the same dosage of Astressin-B but that have different CRF levels. Objectively we want to study how the compound behaves and counteracts in the presence of a blocking peripheral CRF receptors molecular switching mechanism with different pre-existing organism strain factors.

For safety reasons we are not going to be specific on dosages at this time. We have translated the CRF into percentages for specification purposes.

Each of the 5 sub-groups had diverse CRF start levels before the treatment initiated; this was the criteria used to group de subjects. Another relevant note regarding the grouping is that all of the subjects have the same approximate age in order to suppress age related factors.

Results (ongoing): The efficiency of the compound decreased as the CRF levels increased. We estimate an overall 24% decline from the lowest CRF Expressing group to the highest. -3% from P-B1 to P-B2, -5% from P-B2 to P-B3, 7% from P-B3 to P-B4, 9% from P-B4 to P-B5. This progression is not surprising at all and was fully expected.

Side Effects: (ongoing) Sub-control group P-B5 and P-B4 subjects showed mild signs of increased saliva production, very mild hypersomnia was also registered curiously on P-B4. So far we have not registered additional side effects on this parcel.

Understandably we have been getting many questions regarding dosages. One thing that is important to note is that we are using dosages that are “in sync” with the weight, age, and metabolism of our subjects; the idea is to have a realistic simulation of the tests that will be conducted during the Human trials.
I will be posting the results on Parcel C sometime during next week. Jason asked me to talk about Cortisol, but I feel that it needs a separate post since it’s such an important and relevant subject, so expect an update on this very soon as well.

Astressin-B Research report – Norma – Parcel A

Jason Wats MD    Astressin-B, Research and latest Discoveries    

Right on time here is an update on project’s ongoing progress;

Currently we have 3 distinct sub-groups in Parcel A that are being given different dosage of the compound, while they are responding to the treatment, the impact is significantly different. As the dose decreases the results also decrease.  There is no substantial difference between the mid-level group and the group that is taking the highest dosage.

In regards to the highest group, 91% of the subjects have showed full recovery, which means they the hair count is a par to the isolated control group. 8% of the remaining subjects are showing significant regrowth, while 1% is showing moderate regrowth.

In the mid-level group 85% of the subjects have showed full recovery, 13% demonstrate significant regrowth, 2% are showing moderate regrowth.

In the lower dosage group 31% of the subjects have showed full recovery, 10% of the remaining subjects demonstrate significant regrowth, 41% are showing moderate regrowth, and 8% of the subjects did not show any signs of regrowth at all.

An interesting side note is that every subject suffering from Cushing’s syndrome has showed full recovery, regardless of the dosage that it was given, we will elaborate more on this in the next report.

Within Parcel B there are 5 sub-groups, each being given the same dosage of the compound. These groups have been divided CRF levels. We cannot get into specific results about this parcel since we are yet to process all of the data.

I asked Sarah to post a complementary report on Parcel B and C this week, she will also be covering the following issues; Cortisol levels, Why this experiment is relevant of Androgenic Alopecia patients and side effects,  so stay tuned.

p.s. you might have noticed the name “Norma”  in the title of the post, it is the internal “code” we have given to our research project, a mere triviality to most, but significant to us since it is  a tribute to someone very dear to our team that passed away last year.

Research Project’s Schedule

Sarah Campeau    Astressin-B, Research and latest Discoveries    

Let me start by thanking everyone for the continuous support. We decided to share with all of you the schedule of our ongoing Research project just in case you would like to schedule your visits to our website.

Between 10^th and 15^th August: Project status update

Between 15^th and 1^th September: Final project status update

Between 1th and 15^th October: Preliminary Report

Between 15^th of October and 5^th November:  Public release of the final report

Between 1^th of December and 1^th March 2012: Human Trials Phase 1  (Subject to change) Not conducted by this Research group.

Human Trials

Sarah Campeau    Astressin-B, Research and latest Discoveries    

Since we have been getting a lot of questions about the possibility of our group conducting Human trial testing we decided to provide more information in this regard.

In order to conduct human testing of any kind there needs to be a licensing process that is not diligent and that we don’t feel prepared for.

That is not to say that we are not qualified to conduct the tests, as matter of fact Jason has lead numerous projects that involved human testing, but we feel the project would be better served if the Human trials were done by a team that was not involved in the initial research.

Rest assured that we have already two partners well positioned to carry out the testing on our terms. What does this mean? Well, it means that the laboratory that we will carry on our will not be allowed to patent the discovery, sell it or distribute it in any way.

We are looking for a treatment that has proven to work and brings consistent results, rushing things is not the solution.

Our team will also be directly involved with the Human trials, without interfering with the methodology of the laboratory.

Astressin-B Media Coverage – Part 1

admin    Astressin-B, Research and latest Discoveries    

An old video for those of you who missed the media coverage on the first test conducted with Astressin-B.

Products containing Astressin-b

admin    Astressin-B, Research and latest Discoveries     Astressin-B

Have to issue this alert, we have been receiving considerable volume of e-mail asking us about commercial products that contain Astressin-B. We also received a great number of links of supplements that allegedly had the compound. (curiously most of them were soy based)

At this moment there is no such thing as a commercial treatment based on Astressin-b, the compound is still in the early trials, and has not been integrated into any supplement or existing treatment.

If you find a product that claims to be using Astressin-b, please mail us the link and don’t waste your money on a product that isn’t legitimate and won’t be beneficial to you in any way.

Note: Will be adding this notice to our consumer alerts.

Astressin-B Trial Status

admin    Astressin-B, Research and latest Discoveries    

We finally managed to get back here and give you a quick status update on our tests.
Preliminary results almost leave no question regarding the efficiency of a treatment with this compound on our subjects.
In all honesty I do not believe I have ever seen a bigger potential break through, our subjects not only showed signs of significant regrowth within three months of the treatment, but they did so in staggering record time, the density of the growth and quality of the hair was equally impressive.

So what does this mean for you? First and foremost that there is hope, even better, substantiated hope!
Now please consider that we are testing on university laboratory with very few resources at our disposal, which means that there is a lot that we don’t know and won’t be able to know, specially regarding the chemistry and the interaction process of the compound, but what we can say for sure is this; 100% of the mice we tested under severe stress suffering from alopecia responded to this treatment with moderate to significant regrowth.

It’s no wonder very few main stream media channels are not talking about it, if this lives up to the expectations and the success rate carries on to the Human trials, this will completely change the game and take a lot of drugs from the pharmacy shelves.
We will be posting our final report in 2 months, so keep tuned and most importantly, never lose hope, especially in a moment like this.

Sarah

How Astressin-B Reverses and Prevents Alopecia on mice

admin    Astressin-B, Research and latest Discoveries    

Our own Sarah is leading a couple of small experiments here at Hair Loss Research with anti-stress agents on mice. It’s actually nothing entirely new, and the link between Stress, and the fluctuation in Cortisol levels has long been established. Below is an extract of the research article that lead to these conclusions.

read more

Alopecia accidental Breakthough

admin    Astressin-B, Research and latest Discoveries    

Its been a long long time since we have had such an exciting breakthrough. Here at hairloss-research.com we have had some knowledge about this accidental discovery for a couple of months, but only last week did we receive the actual experiment data. So far, everything looks consistent, but we will keep you updated in the upcoming weeks.

In the meantime, below are some of the media reports on the subject: